BRKR vs ILMN vs BIO Stock Comparison

Bruker, Illumina and Bio-Rad Laboratories Prices as of Nov 13, 2026 Peers: Industry group
BRKR Bruker Corp
$61.59 +10.8% 1M +47.4% 1Y
Market cap
$9.41B
P/E
–
Revenue (TTM)
$3.51B
Div. yield
0.32%
Life Sciences Tools Healthcare
2 wins
ILMN Illumina, Inc.
$207.01 -23.8% 1M +72.6% 1Y
Market cap
$31.30B
P/E
34.9x
Revenue (TTM)
$4.54B
Div. yield
–
Life Sciences Tools Healthcare
6 wins

Head to Head

11 decided of 12

Illumina leads on 6 of the 12 questions below (Illumina 6, Bio-Rad Laboratories 3, Bruker 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBRKRILMNBIOLeader
Larger companyMarket capitalisation $9.41B $31.30B $9.85B ILMN
Cheaper on earningsLower P/E, profitable companies only -56.1x 34.9x 9.6x BIO
Cheaper on forward earningsLower price / next fiscal year consensus EPS 28.0x 40.9x 36.0x BRKR
Faster revenue growthRevenue growth, trailing twelve months +2.2% +5.8% +1.4% ILMN
More profitableNet margin, trailing twelve months -4.8% 19.7% 39.5% BIO
Better return on capitalReturn on invested capital -1.7% 16.6% -0.6% ILMN
Less leveragedLower net debt / EBITDA 10.0x 0.4x — ILMN
Higher dividend yieldTrailing dividend yield 0.32% — — –
Better 1-year returnPrice return, last 12 months +47.4% +72.6% +15.5% ILMN
Better 5-year returnAnnualised price return, 5 years -5.7%/yr -11.1%/yr -13.5%/yr BRKR
Less volatileAnnualised volatility, 1 year 62.4% 51.1% 36.5% BIO
Higher overall scoreMean of the five percentile scores vs peers 48/100 75/100 70/100 ILMN

Percentile Scorecard

BRKRILMNBIO

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBRKRILMNBIO
Valuation 69 #77 of 243 63 #91 of 243 85 #38 of 243
Growth 18 #187 of 228 73 #63 of 228 48 #120 of 228
Profitability 63 #82 of 222 98 #5 of 222 70 #67 of 222
Financial Health 19 #200 of 248 57 #107 of 248 66 #85 of 248
Shareholder Returns 69 #50 of 158 85 #25 of 158 80 #32 of 158
Overall 48 75 70
  • BRKR ranked among 252 companies in Medical Devices and Diagnostics
  • ILMN ranked among 252 companies in Medical Devices and Diagnostics
  • BIO ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBRKRILMNBIOSPY
1 month +10.8%-23.8%+1.0% -2.0%
3 months +6.7%+8.4%+2.8% -2.8%
6 months +43.6%+45.2%+47.9% +2.0%
Year to date +30.7%+57.8%+20.8% +10.6%
1 year +47.4%+72.6%+15.5% +12.2%
3 years -0.1%+118.3%+19.1% +68.1%
3 years, per year 0.0%+29.7%+6.0% +18.9%
5 years -25.4%-44.5%-51.6% +61.4%
5 years, per year -5.7%-11.1%-13.5% +10.1%
10 years +169.3%+54.5%+119.6% +248.5%
10 years, per year +10.4%+4.4%+8.2% +13.3%

Risk

MeasureBRKRILMNBIOSPY
Volatility, 1Y 62.4%51.1%36.5% 13.6%
Downside volatility, 1Y 59.9%50.9%35.6% 13.9%
Beta vs S&P 500, 1Y 1.751.110.75 1.00
Return / volatility, 1Y 0.761.420.43 0.90
Max drawdown, 5Y -68.9%-82.9%-72.2% -25.4%
From 52-week high -7.4%-29.5%-6.2% -3.2%
52-week high $66.54$293.69$390.34 $779.14
52-week low $32.76$114.44$241.71 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBRKRILMNBIO
P/E now vs peer median -56.1xmedian 26.5x 34.9xmedian 26.5x 9.6xmedian 26.5x
P/S now vs peer median 2.7xmedian 2.7x 6.9xmedian 2.7x 3.8xmedian 2.7x
EV/EBITDA now vs peer median 69.3xmedian 18.4x 25.7xmedian 18.4x —median 18.4x
P/FCF now vs peer median 38.4xmedian 25.4x 29.6xmedian 25.4x 29.9xmedian 25.4x
P/B now vs peer median 4.1xmedian 2.5x 10.0xmedian 2.5x 1.3xmedian 2.5x
PEG now vs peer median 1.57median 0.98 0.85median 0.98 0.09median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBRKRILMNBIO
Revenue $3.51B $4.54B $2.59B
Gross profit $1.67B $3.08B $1.33B
Operating income -$69.80M $960.00M -$61.90M
Net income -$115.70M $895.00M $1.02B
Free cash flow $244.70M $1.06B $329.10M
R&D $387.20M $975.00M $265.80M
EPS (diluted) $-1.10 $5.81 $37.96
Cash & equivalents $119.70M $1.29B $465.30M
Total debt $1.71B $1.79B $1.20B
Shares (diluted) 152.50M 154.00M 26.95M
Enterprise value $8.71B $26.01B $3.46B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBRKRILMNBIO
P/E -56.1x 34.9x 9.6x
P/FCF 38.4x 29.6x 29.9x
P/Operating cash flow 27.5x 25.4x 21.0x
P/S 2.7x 6.9x 3.8x
P/B 4.1x 10.0x 1.3x
P/Tangible book 4.2x 11.4x 1.3x
EV/EBITDA 69.3x 25.7x –
EV/EBIT -157.6x 33.1x -151.6x
EV/Revenue 3.1x 7.0x 3.6x
EV/FCF 45.0x 30.0x 28.5x
EV/Operating cash flow 32.2x 25.8x 20.1x
PEG (3Y EPS CAGR) 1.57 0.85 0.09

Growth

14 metrics
MetricBRKRILMNBIO
Revenue growth (1Y) 2.2% 5.8% 1.4%
Revenue CAGR (3Y) 7.6% -0.7% -1.6%
Gross profit growth (1Y) 3.2% 8.5% -0.6%
Gross profit CAGR (3Y) 4.9% 4.4% -3.0%
Operating income growth (1Y) -209.1% 23.1% -127.6%
Operating income CAGR (3Y) -29.1% 30.0% -29.5%
Net income growth (1Y) -390.3% 27.5% 251.3%
Net income CAGR (3Y) -33.1% 40.9% 103.5%
EPS growth (1Y) -602.7% 27.5% 251.2%
EPS CAGR (3Y) -35.8% 41.2% 107.7%
Operating cash flow growth (1Y) 262.5% 9.6% -4.8%
Operating cash flow CAGR (3Y) 2.6% 47.5% 7.8%
Free cash flow growth (1Y) 2,408% 5.7% -2.3%
Free cash flow CAGR (3Y) 5.9% 126.5% 13.6%

Profitability

14 metrics
MetricBRKRILMNBIO
Gross margin 47.7% 67.9% 51.3%
EBITDA margin 4.5% 27.3% –
Operating margin -2.0% 21.2% -2.4%
Pretax margin -2.0% 23.3% 50.9%
Net margin -4.8% 19.7% 39.5%
FCF margin 7.0% 23.3% 12.7%
Operating cash flow margin 9.7% 27.1% 18.1%
Return on equity -4.9% 29.9% 13.8%
Return on assets -2.0% 13.3% 9.7%
Return on invested capital -1.7% 16.6% -0.6%
Return on capital employed -1.5% 17.2% -0.6%
Asset turnover 0.6x 0.7x 0.2x
Cash conversion (OCF / net income) -3.0x 1.4x 0.5x
Stock comp / revenue – 5.9% 2.4%

Financial Health

11 metrics
MetricBRKRILMNBIO
Debt / assets 29.4% 26.3% 11.2%
Debt / equity 0.7x 0.6x 0.2x
Net debt / EBITDA 10.0x 0.4x –
Debt / FCF 7.0x 1.7x 3.7x
Liabilities / assets 60.4% 53.8% 29.5%
Equity / assets 39.6% 46.2% 70.5%
Interest coverage -1.2x 9.8x -1.3x
Current ratio 1.8x 2.6x 3.2x
Quick ratio 0.7x 1.8x 2.2x
Cash ratio 0.1x 1.2x 1.7x
Altman Z-score – 6.62 3.41

Shareholder Returns

7 metrics
MetricBRKRILMNBIO
Dividend yield 0.3% – –
Net buyback yield – 1.2% 0.7%
Shareholder yield 0.3% 1.2% 0.7%
Payout ratio (earnings) -26.2% – –
Payout ratio (FCF) 12.4% – –
Dividend growth (1Y) 32.3% – –
Dividend CAGR (3Y) 0.9% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBRKRILMNBIO
Forward P/E 28.0xFY2026 40.9xFY2026 36.0xFY2026
EPS, next fiscal year $2.20FY2026 $5.06FY2026 $10.18FY2026
EPS growth, next FY +20.2%FY2026 +4.5%FY2026 +2.6%FY2026
EPS growth, the year after +5.5% +25.1% -0.2%
Revenue, next fiscal year $3.76BFY2026 $4.53BFY2026 $2.69BFY2026
Revenue growth, next FY +9.4%FY2026 +4.4%FY2026 +4.2%FY2026
Revenue growth, the year after +2.7% +12.6% -7.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBRKRILMNBIO
Held by institutions 93.1% 100.0% 89.5%
Institutions holding 418 935 405
Change in shares held, QoQ +3.6% +0.0% -2.9%
Institutions buying 249 464 177
Institutions selling 122 331 157
Buyers to sellers 2.04 1.40 1.13

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BRKRILMNBIO
BRKR 1.00 0.51 0.48
ILMN 0.51 1.00 0.35
BIO 0.48 0.35 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BRKR, ILMN and BIO?

Illumina (ILMN) is the largest by market capitalisation: Bruker (BRKR) $9.41B, Illumina (ILMN) $31.30B, Bio-Rad Laboratories (BIO) $9.85B.

Which stock is cheaper, BRKR, ILMN and BIO?

Bio-Rad Laboratories (BIO) trades on the lowest price-to-earnings ratio (Bruker (BRKR) -56.1x, Illumina (ILMN) 34.9x, Bio-Rad Laboratories (BIO) 9.6x). On next year's consensus earnings, Bruker (BRKR) is cheapest (Bruker (BRKR) 28.0x, Illumina (ILMN) 40.9x, Bio-Rad Laboratories (BIO) 36.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Illumina (ILMN) grew revenue fastest over the trailing twelve months: Bruker (BRKR) +2.2%, Illumina (ILMN) +5.8%, Bio-Rad Laboratories (BIO) +1.4%.

Which company is more profitable?

Bio-Rad Laboratories (BIO) has the highest net margin (Bruker (BRKR) -4.8%, Illumina (ILMN) 19.7%, Bio-Rad Laboratories (BIO) 39.5%). On return on invested capital, Illumina (ILMN) leads (Bruker (BRKR) -1.7%, Illumina (ILMN) 16.6%, Bio-Rad Laboratories (BIO) -0.6%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Bruker (BRKR) +47.4%, Illumina (ILMN) +72.6%, Bio-Rad Laboratories (BIO) +15.5%. Over five years, Bruker (BRKR) compounded fastest (Bruker (BRKR) -5.7%/yr, Illumina (ILMN) -11.1%/yr, Bio-Rad Laboratories (BIO) -13.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Bruker (BRKR) 0.32%. Illumina (ILMN) and Bio-Rad Laboratories (BIO) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Bio-Rad Laboratories (BIO) has been the steadiest (Bruker (BRKR) 62.4%, Illumina (ILMN) 51.1%, Bio-Rad Laboratories (BIO) 36.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BRKR, ILMN and BIO?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Illumina (ILMN) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.